NCT07757048Completed
A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States
Current Treatment Patterns and Real-World Outcomes of Patients With IgA Nephropathy in the United States
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
The aim of this study was to characterize real-world treatment patterns, including therapy sequences, escalation, and duration, and treatment outcomes in IgA nephropathy (IgAN) patients in the United States (US). The study used data which has detailed information on renal biopsy and laboratory data, linked with medical and pharmacy claims.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 6286 (actual)
- First submitted
- 5 Aug 2026
- Start date
- 12 Mar 2026
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- IgA nephropathy
- NCT number
- NCT07757048
What you commit to
- Study type: Observational
- Participants enrolled: 6286
- From 12 Mar 2026 to the primary completion date, 1 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of systemic lupus erythematosus (SLE), lupus nephritis (LN), IgA vasculitis (IgAV), chronic liver disease, and Minimal Change Disease (MCD) with IgA deposition at any time during the study period.
- Treatment Escalation Cohort:
- Presence of SLE, LN, IgAV, chronic liver disease, and MCD with IgA deposition at any time during the study period.
Lab values
- Any evidence of kidney failure as defined by estimated glomerular filtration rate (eGFR) \<15 ml/min/1.73 m², International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes for chronic kidney disease (CKD) stage 5, Current Procedural Terminology (CPT) codes for kidney transplant or dialysis prior to RAASi initiation.
- Received any corticosteroids/mycophenolate mofetil (MMF), sodium-glucose co-transporter 2 inhibitor (SGLT2i), or IgAN branded therapies prior to the end of the 90 days of RAASi treatment.
Other
- IgAN Cohort:
Who the study is looking for
- IgAN Cohort:
- Renal biopsy confirming IgAN during the patient identification period.
- Age ≥18 at index. The index date was the date of first claim or biopsy.
- ≥182 days of continuous enrollment in medical and pharmacy claims before index date.
- ≥365 days of continuous enrollment in medical and pharmacy claims following (and including) index date.
- Treatment Escalation Cohort:
- Renal biopsy confirming IgAN during the patient identification period.
- Age ≥18 at index.
- ≥182 days of continuous enrollment in medical and pharmacy claims before index date.
- ≥182 days of continuous enrollment in medical and pharmacy claims following (and including) index date.
- Evidence of treatment with a renin-angiotensin-aldosterone system inhibitor (RAASi) for \> 3 months following IgAN diagnosis date.
- ≥1 urine protein creatinine ratio (UPCR) lab measurement following the index date.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.